Repeat doses of the intrathecal antisense oligonucleotide nusinersen in children with infantile-onset spinal muscular atrophy (SMA) continue to demonstrate safety, according to early data from the phase III SHINE extension study, bringing considerable hope to the SMA community.
Individuals who have failed between two and four preventive therapies for episodic migraine may derive benefit from a once-a-month dose of erenumab, according to results of the phase IIIb LIBERTY* study.
The oral CGRP* receptor antagonist ubrogepant significantly reduced headache pain and bothersome migraine-associated symptom of a single-attack, acute migraine, according to the ACHIEVE** I study presented at AAN 2018.
High intake of fish enriched with omega-3 polyunsaturated fatty acids (PUFAs) combined with fish oil supplements were associated with a lower risk of developing multiple sclerosis (MS), according to the MS Sunshine Study presented at the AAN 2018 Annual Meeting.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Long-term treatment with the interleukin-5
receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.